BCRX  Biocryst Pharmaceuticals Inc.




Health Care


Biotechnology: Biological Products (No Diagnostic Substances)

Market Cap.


Vuru Grade


Current Price

+0.08 (+0.52%)

Stability Price

Overvalued by 98.58%

Company Metrics

  • 0 P/E
  • 65.19 P/S
  • 17.18 P/B
  • -0.72 EPS
  • -229.93% Cash ROIC
  • 1.26 Cash Ratio
  • 0 / 0% Dividend
  • 908,491.00 Avg. Vol.
  • 1.11B Market Cap.

Company Description

BioCryst Pharmaceuticals, Inc. designs, optimizes, and develops small-molecule pharmaceuticals that block key enzymes involved in infectious diseases, cancer, and inflammatory diseases. It uses structure-based drug design, which incorporates multiple scientific disciplines, including biology, crystallography, medicinal chemistry, and computer modeling to develop new therapeutic candidates. The com...

Download 10 Years of Financial Statements:
Income Statement   Balance Sheet   Cash Flow


Zacks Rating on BioCryst Pharmaceuticals, Inc.
American Trade Journal - Jul 30, 2015
BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) remains a strong buy in the latest set of rankings. The shares have received an average rating of 1.29 by 7 analysts.
Durham's BioCryst cuts $45 million deal with Australian firm
Triangle Business Journal - Jun 17, 2015
Durham-based BioCryst Pharmaceuticals, Inc., (Nasdaq: BCRX) licensed its recently approved flu treatment Rapivap in a deal that could bring the company $45 million plus sales royalties.
BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) has licensed RAPIVAB (peramivir ... - Inside Trade
BioCryst Licenses Worldwide Rights to Commercialize RAPIVAB(R) Influenza ... - GlobeNewswire (press release)
Biocryst Pharmaceuticals Inc (BCRX) Files Form 4 Insider Selling : Thomas R Ii ...
Insider Trading Report - Jul 22, 2015
Biocryst Pharmaceuticals Inc (BCRX): Thomas R Ii Staab , Senior Vice President and CFO of Biocryst Pharmaceuticals Inc sold 3,500 shares on Jul 20, 2015. The Insider selling transaction was disclosed on Jul 22, 2015 to the Securities and Exchange ...
BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Short Interest Update
OTC Outlook - Jul 28, 2015
BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX), A reduction of 272,206 shares or 2.8% was observed in the short interest of BioCryst Pharmaceuticals, Inc. The interest on July 15,2015 came in at 9,380,714 shares and as per the average daily trading of ...
Biocryst Pharmaceuticals Inc (BCRX) Discloses Form 4 Insider Selling : Exec ... - American Trade Journal
Morning Watch List: BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX), Alcatel ... - Stock Transcript
Stock Report on BioCryst Pharmaceuticals Inc (NASDAQ:BCRX)
Street Report - Jul 1, 2015
[Zacks] BioCryst Pharmaceuticals Inc (NASDAQ:BCRX)(TREND ANALYSIS) was a big mover last session with its shares rising nearly 10% on the day.
BioCryst Pharmaceuticals Stock Rating Upgraded by Bank of America (BCRX) - The Legacy
Top Growth Pick: BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) - Enterprise Leader
Warning BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) optimists! Thomas Staab ...
OctaFinance.com - Jul 22, 2015
Thomas Staab, the Senior Vice President and CFO of BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) 15.26 0.00 0.00% , unloaded 3,500 shares of the company, valued at $57,750 U.S Dollars, estimated based on $16.5 a share.
Analyst Price Target Update on BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) - American Trade Journal
BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Stock Rating Update - Investor Newswire
Why BioCryst Pharmaceuticals, Inc. Shares Scorched Higher
Motley Fool - Apr 1, 2015
What: Shares of BioCryst Pharmaceuticals (NASDAQ:BCRX), a predominantly clinical-stage biotech company focused on developing novel small molecule drugs to treat varying diseases, scorched higher by as much as 12% in Wednesday's trading session ...
BioCryst Pharmaceuticals (BCRX) Jumps: Stock Adds 5.4% - Zacks.com
Ebola Finances Coming Back in the News - 24/7 Wall St.
Company Shares of BioCryst Pharmaceuticals, Inc. Rally 3.81%
Insider Trading Report - Jul 20, 2015
Shares of BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) rose by 3.81% in the past week and 3.01% for the last 4 weeks.
BioCryst Pharmaceuticals Given Consensus Rating of "Buy" by Analysts (NASDAQ:BCRX) - sleekmoney
News Buzz - BioCryst Pharmaceuticals (BCRX), Anacor Pharmaceuticals (ANAC ... - Techsonian (press release)
BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Analyst Rating Update
Money Flow Index - Jul 16, 2015
Biocryst Pharmaceuticals (NASDAQ:BCRX) has received a short term rating of sell from research analysts at Zacks with a rank of 4. The company has been rated an average of 1.29 by 7 Wall Street Analysts. 6 analysts have added the shares in their list of ...
Analyst Price Target Update on BioCryst Pharmaceuticals, Inc. - Insider Trading Report
BioCryst Pharmaceuticals Short Interest Down 19.9% in June (BCRX) - Mideast Time
Short Interest Update of BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX)
Money Flow Index - Jul 14, 2015
The short interest in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) has declined from 12,053,092 on June 15,2015 to 9,652,920 on June 30,2015.
Will BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Surprise This Quarter? - Investor Newswire
BioCryst Pharmaceuticals Lowered to Sell at Zacks (BCRX) - Dakota Financial News